ArticleNature medicine2017
Defining total-body AIDS-virus burden with implications for curative strategies.
Open access · greenAbstract read
In one paragraph
Article in Nature medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 309 papers.
0numbers the graph read from it
0cells of the map it votes in
309citing papers in PubMed
24.0field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
309 citing papers in PubMed, 403 citations in OpenAlex.
- Doubling dolutegravir dosage reduces the viral reservoir in ART-treated people with HIV.eLife · 2026Trial
- Impact of Dolutegravir Plus Lamivudine as First-line Antiretroviral Treatment on the Human Immunodeficiency Virus Type 1 Reservoir and Inflammatory Markers in Peripheral Blood.The Journal of infectious diseases · 2025Trial
- Trial
- Early intervention with 3BNC117 and romidepsin at antiretroviral treatment initiation in people with HIV-1: a phase 1b/2a, randomized trial.Nature medicine · 2022Trial
- Paradoxically Greater Persistence of HIV RNA-Positive Cells in Lymphoid Tissue When ART Is Initiated in the Earliest Stage of Infection.The Journal of infectious diseases · 2022Trial
- Broadly neutralizing antibodies in adult males living with HIV undergoing analytical treatment interruption: secondary and exploratory outcomes of the phase II randomized controlled RIO trial.Nature medicine · 2026Article
- Multi-omics links microbial dysbiosis, systemic inflammation, and metabolomic disruptions to SNAE risk in treated HIV.JCI insight · 2026Article
- The brain as an HIV reservoir: Recent findings using autopsy tissues from people with HIV.PLoS pathogens · 2026Review
- CD56bioRxiv : the preprint server for biology · 2026Article
- Three immunoregulatory signatures define non-productive HIV infection in stem cell memory CD4Nature communications · 2026Article
- HIV Reservoirs in Brain parenchyma and Cerebrospinal Fluid During Suppressive ART: Same-Same or Very Different?Current HIV/AIDS reports · 2026Review
- Multiplex engineering of rhesus macaque NK cells enhances homing to sites of HIV replication in B cell follicles.bioRxiv : the preprint server for biology · 2026Article
- Identification of the cellular factor KLF16 as a novel epigenetic repressor of HIV-1 transcription.Research square · 2026Article
- A novel measure of antiretroviral activity in cerebrospinal fluid and association with HIV persistence and cognitive function.AIDS (London, England) · 2026Article
- Identification of the cellular transcription factor KLF16 as a novel repressive epigenetic repressor of HIV-1 transcription.bioRxiv : the preprint server for biology · 2026Article
- Recapitulating the qualities of HIV-specific CD8 + T cells from spontaneous controllers.Current opinion in HIV and AIDS · 2026Review
- Multi-omics links microbial dysbiosis, systemic inflammation and metabolomic disruptions to SNAE risk in treated HIV.bioRxiv : the preprint server for biology · 2026Article
- HIV Reservoirs Across Multiple Tissues: From Heterogeneous Mechanisms to Therapeutic Targeting.Microorganisms · 2026Review
- A Tissue Virus Microenvironment with Activated Stress Responses Underlies Durable SIV Persistence.bioRxiv : the preprint server for biology · 2026Article
- Linking gut microbiome to HIV-1 reservoir size in people living with HIV.Gut pathogens · 2026Article
249 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
32 authors at 7 institutions in 2 countries.
Jacob D EstesAIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, Maryland, USA.
Cissy KityoJoint Clinical Research Center, Kampala, Uganda.
Francis SsaliJoint Clinical Research Center, Kampala, Uganda.
Louise SwainsonDivision of Experimental Medicine, University of California, San Francisco, San Francisco, California, USA.
Krystelle Nganou MakamdopVaccine Research Center, National Institutes of Health, Bethesda, Maryland, USA.
Gregory Q Del PreteAIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, Maryland, USA.
Steven G DeeksDepartment of Medicine, University of California, San Francisco, San Francisco, California, USA.
Paul A LuciwDepartment of Pathology and Laboratory Medicine, University of California, Sacramento, Sacramento, California, USA.
Jeffrey G ChipmanDepartment of Surgery, University of Minnesota, Minneapolis, Minnesota, USA.
Gregory J BeilmanDepartment of Surgery, University of Minnesota, Minneapolis, Minnesota, USA.ORCID http://orcid.org/0000-0001-5036-3027
Torfi HoskuldssonDepartment of Surgery, University of Minnesota, Minneapolis, Minnesota, USA.
Alexander KhorutsDepartment of Medicine, University of Minnesota, Minneapolis, Minnesota, USA.
Jodi AndersonDepartment of Medicine, University of Minnesota, Minneapolis, Minnesota, USA.
Claire DeleageAIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, Maryland, USA.
Jacob JasurdaDepartment of Medicine, University of Minnesota, Minneapolis, Minnesota, USA.
Thomas E SchmidtDepartment of Medicine, University of Minnesota, Minneapolis, Minnesota, USA.
Michael HafertepeDepartment of Medicine, University of Minnesota, Minneapolis, Minnesota, USA.
Samuel P CallistoDepartment of Medicine, University of Minnesota, Minneapolis, Minnesota, USA.ORCID http://orcid.org/0000-0003-3148-2498
Hope PearsonDepartment of Medicine, University of Minnesota, Minneapolis, Minnesota, USA.
Thomas ReimannDepartment of Medicine, University of Minnesota, Minneapolis, Minnesota, USA.
Jared SchusterDepartment of Medicine, University of Minnesota, Minneapolis, Minnesota, USA.
Jordan SchoephoersterDepartment of Medicine, University of Minnesota, Minneapolis, Minnesota, USA.
Peter SouthernDepartment of Microbiology and Immunology, University of Minnesota, Minneapolis, Minnesota, USA.
Katherine PerkeyDepartment of Microbiology and Immunology, University of Minnesota, Minneapolis, Minnesota, USA.
Liang ShangDepartment of Microbiology and Immunology, University of Minnesota, Minneapolis, Minnesota, USA.
Stephen W WietgrefeDepartment of Microbiology and Immunology, University of Minnesota, Minneapolis, Minnesota, USA.
Courtney V FletcherCollege of Pharmacy, University of Nebraska Medical Center, Omaha, Nebraska, USA.
Jeffrey D LifsonAIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, Maryland, USA.
Daniel C DouekVaccine Research Center, National Institutes of Health, Bethesda, Maryland, USA.
Joseph M McCuneDivision of Experimental Medicine, University of California, San Francisco, San Francisco, California, USA.
Ashley T HaaseDepartment of Microbiology and Immunology, University of Minnesota, Minneapolis, Minnesota, USA.
Timothy W SchackerDepartment of Medicine, University of Minnesota, Minneapolis, Minnesota, USA.
University of Minnesota · USLeidos (United States) · USUniversity of California, San Francisco · USJoint Clinical Research Centre · UGNational Institutes of Health · USCalifornia State University, Sacramento · USUniversity of Nebraska Medical Center · US
Funding
National Institute on Aging (NIA) ColonyP51OD011107 · OD · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Simon J. Atkinson · 2012 to 2026
$191.5MVirology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MALLORY O JOHNSON · 1988 to 2026
$93.6MUniversity of Minnesota Clinical and Translational Science Institute (UMN CTSI)UL1TR000114 · NCATS · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R · 2012 to 2015
$35.0MViral reservoirs and sanctuaries in HAART - treated patients: role and mechanismsU19AI096109 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PALMER, SARAH ELIZABETH · 2011 to 2015
$29.5MVirological Measurements of Cryptic ReplicationP01AI074340 · NIAID · UNIVERSITY OF MINNESOTA · PI SCHACKER, TIMOTHY W · 2008 to 2012
$12.1MThe Lymphoid Tissue Pharmacology of Antiretroviral DrugsR01AI124965 · NIAID · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI FLETCHER, COURTNEY V · 2016 to 2020
$3.7MNCATS NIH HHS UL1 TR000114NIAID NIH HHS P01 AI074340NIAID NIH HHS P30 AI027763NIAID NIH HHS R01 AI124965NIAID NIH HHS U19 AI096109NIH HHS P51 OD011107
Abstract
In the quest for a functional cure or the eradication of HIV infection, it is necessary to know the sizes of the reservoirs from which infection rebounds after treatment interruption. Thus, we quantified SIV and HIV tissue burdens in tissues of infected nonhuman primates and lymphoid tissue (LT) biopsies from infected humans. Before antiretroviral therapy (ART), LTs contained >98% of the SIV RNA
Indexed as
Viral LoadAnti-HIV AgentsDNA, ViralHIVHIV InfectionsHumansLymphoid TissueRNA, ViralAnti-HIV AgentsDNA, ViralRNA, Viral
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.